A ctDNA assay for remote monitoring and risk stratification

Presented Alexey Aleshin, MD, Senior Medical Director Oncology, Natera

[barisakmansoy]

Mr. Aleshin,
In the era of new developments about cancer treatment & monitoring, first of all thanks for your crystal clear and compherensive speech about ctDNA biotechnological developments with Signatera, especially in colorectal cancer. I am also very satisfied with your patient samples cases during your presentation. At the end of the session, highly qualified Q&A session was fully satisfactory in terms of cancer clinical practice strategies....